Children with Crohn’s disease are at higher risk of developing perianal fistulas ... These deleterious effects often occur in children and are difficult to treat. Therefore, early treatment or ...

22, 2024 — A large-scale clinical trial of treatment strategies for Crohn's disease ... and children ... Developing a Less Invasive Test for Inflammatory Bowel Disease Sep.

Remestemcel-L is under clinical development by Mesoblast and currently in Phase III for Crohn's Disease (Regional Enteritis).

Steqeyma is approved for adult and pediatric patients with plaque psoriasis and active psoriatic arthritis as well as adults ...

Early treatment of pediatric Crohn's disease with anti-tumor necrosis factor medications can substantially reduce the risk of ...

Infliximab biosimilar is under clinical development by Celltrion and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

A recent study reveals that anti-TNF drugs significantly reduce the risk of anal fistulas in children with Crohn's disease.

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease, a new ...

Ustekinumab-stba, manufactured by Celltrion, is expected to be marketed in the United States in February 2025.

A study from University of Michigan researchers may provide an explanation for why some patients with Crohn's disease continue to experience symptoms, even in the absence of inflammation.